Anocca Is A Clinical Stage Biopharmaceutical Company Based In Sa Derta Ljeswedenfounded In 2014The Company Focuses On Decoding T Cell Immunity To Create Precision Immunotherapiesanocca Has Raised Over $110 Million In Funding And Is Currently In The Series C Stageit Transitioned To Clinical Stage Status In March 2025 After Receiving Authorization For Its First In Human Trial Anocca Specializes In T Cell Receptor Engineered T Cell Therapiestcr Taimed At Treating Oncologyinfectious Diseasesand Autoimmune Conditionsits Proprietary Platform Integrates Human Cell Based T Cell Biologynon Viral Gene Editing Manufacturingand The Anoccaos Software Ecosystem To Identify Therapeutic Targets And Develop Personalized Treatmentsthe Lead Candidateanoc 001Is Part Of The Vidar 1 Trial For Advanced Pancreatic Cancermarking A Significant Advancement In Non Viral Gene Edited Tcr T Therapiesanocca Collaborates With Leading Medical Centers Across Europe To Conduct Its Clinical Trialsfocusing On Solid Tumors That Are Resistant To Conventional Treatments
